Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.
<h4>Background</h4>Data on suppression of HIV replication in the CNS and on the subsequent risk of neurocognitive impairment using monotherapy with boosted protease inhibitors are limited.<h4>Methods</h4>Ours was an exploratory cross-sectional study in patients on lopinavir/r...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0070201 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850119051921063936 |
|---|---|
| author | José R Santos José A Muñoz-Moreno José Moltó Anna Prats Adrià Curran Pere Domingo Josep M Llibre Daniel R McClernon Isabel Bravo Jaume Canet Victoria Watson David Back Bonaventura Clotet |
| author_facet | José R Santos José A Muñoz-Moreno José Moltó Anna Prats Adrià Curran Pere Domingo Josep M Llibre Daniel R McClernon Isabel Bravo Jaume Canet Victoria Watson David Back Bonaventura Clotet |
| author_sort | José R Santos |
| collection | DOAJ |
| description | <h4>Background</h4>Data on suppression of HIV replication in the CNS and on the subsequent risk of neurocognitive impairment using monotherapy with boosted protease inhibitors are limited.<h4>Methods</h4>Ours was an exploratory cross-sectional study in patients on lopinavir/ritonavir-based monotherapy (LPV/r-MT) or standard triple therapy (LPV/r-ART) for at least 96 weeks who maintained a plasma viral load <50 copies/mL. HIV-1 RNA in CSF was determined by HIV-1 SuperLow assay (lower limit of detection, 1 copy/mL). Neurocognitive functioning was assessed using a recommended battery of neuropsychological tests covering 7 areas. Neurocognitive impairment (NCI) was determined and also a global deficit score (GDS) for study comparisons.<h4>Results</h4>Seventeen patients on LPV/r-MT and 17 on LPV/r-ART were included. Fourteen (82.4%) patients on LPV/r-MT and 16 (94.1%) on LPV/r-ART had HIV-1 RNA <1 copy/mL in CSF (p = 0.601). NCI was observed in 7 patients on LPV/r-MT and in 10 on LPV/r-ART (41% vs 59%; p = 0.494). Mean (SD) GDS was 0.22 (0.20) in patients on LPV/r-MT and 0.47 (0.34) in those on LPV/r-ART (p = 0.012).<h4>Conclusions</h4>Suppression of HIV in CSF is similar in individuals with durable plasma HIV-1 RNA suppression who are receiving LPV/r-MT or LPV/r-ART for at least 96 weeks. Findings for HIV-1 replication in CSF and neurocognitive status indicate that this strategy seems to be safe for CNS functioning. |
| format | Article |
| id | doaj-art-376a141efd7f4d9d8044cf1f4c7da23a |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-376a141efd7f4d9d8044cf1f4c7da23a2025-08-20T02:35:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0187e7020110.1371/journal.pone.0070201Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.José R SantosJosé A Muñoz-MorenoJosé MoltóAnna PratsAdrià CurranPere DomingoJosep M LlibreDaniel R McClernonIsabel BravoJaume CanetVictoria WatsonDavid BackBonaventura Clotet<h4>Background</h4>Data on suppression of HIV replication in the CNS and on the subsequent risk of neurocognitive impairment using monotherapy with boosted protease inhibitors are limited.<h4>Methods</h4>Ours was an exploratory cross-sectional study in patients on lopinavir/ritonavir-based monotherapy (LPV/r-MT) or standard triple therapy (LPV/r-ART) for at least 96 weeks who maintained a plasma viral load <50 copies/mL. HIV-1 RNA in CSF was determined by HIV-1 SuperLow assay (lower limit of detection, 1 copy/mL). Neurocognitive functioning was assessed using a recommended battery of neuropsychological tests covering 7 areas. Neurocognitive impairment (NCI) was determined and also a global deficit score (GDS) for study comparisons.<h4>Results</h4>Seventeen patients on LPV/r-MT and 17 on LPV/r-ART were included. Fourteen (82.4%) patients on LPV/r-MT and 16 (94.1%) on LPV/r-ART had HIV-1 RNA <1 copy/mL in CSF (p = 0.601). NCI was observed in 7 patients on LPV/r-MT and in 10 on LPV/r-ART (41% vs 59%; p = 0.494). Mean (SD) GDS was 0.22 (0.20) in patients on LPV/r-MT and 0.47 (0.34) in those on LPV/r-ART (p = 0.012).<h4>Conclusions</h4>Suppression of HIV in CSF is similar in individuals with durable plasma HIV-1 RNA suppression who are receiving LPV/r-MT or LPV/r-ART for at least 96 weeks. Findings for HIV-1 replication in CSF and neurocognitive status indicate that this strategy seems to be safe for CNS functioning.https://doi.org/10.1371/journal.pone.0070201 |
| spellingShingle | José R Santos José A Muñoz-Moreno José Moltó Anna Prats Adrià Curran Pere Domingo Josep M Llibre Daniel R McClernon Isabel Bravo Jaume Canet Victoria Watson David Back Bonaventura Clotet Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. PLoS ONE |
| title | Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. |
| title_full | Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. |
| title_fullStr | Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. |
| title_full_unstemmed | Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. |
| title_short | Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. |
| title_sort | virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long term monotherapy based on lopinavir ritonavir an exploratory study |
| url | https://doi.org/10.1371/journal.pone.0070201 |
| work_keys_str_mv | AT josersantos virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT joseamunozmoreno virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT josemolto virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT annaprats virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT adriacurran virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT peredomingo virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT josepmllibre virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT danielrmcclernon virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT isabelbravo virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT jaumecanet virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT victoriawatson virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT davidback virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy AT bonaventuraclotet virologicalefficacyincerebrospinalfluidandneurocognitivestatusinpatientswithlongtermmonotherapybasedonlopinavirritonaviranexploratorystudy |